Circulating protein biomarkers of necrotizing enterrocolitis
AssigneeThe Regents of the University of Colorado, a body corporate
InventorJesse Davidson
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, devices, and systems for accurately detecting and/or diagnosing a child having or at risk of developing necrotizing enterocolitis (NEC). In most embodiments, the child is currently suffering from congenital heart disease (CHD). The disclosed methods, devices, and systems may be useful in monitoring the administration and/or response to therapy for CHD and/or NEC. The disclosed methods, devices, and systems may involve detecting one or more biomarkers in a sample from the child, for example a plasma sample, wherein the sample is less than or equal to about 20 microliters.
Claims20
A composition for diagnosing or predicting NEC comprising:
- two or more molecules with affinity for a biomarker, wherein the biomarker is one or more of LRRN1, VASH1, NELL2, DNAJB8, IGFBP1, PTPRN2, AFP, CD74, BST2, CD99, KIR3DL1, RBP2, CES2, NCS1, C4BPB, RAB6A, CCL4, FABP2, FUCA1, REG3A, GGA1, ATXN10, MUC13, ODAM, ARID4B, CCL2, CLEC11A, ITGAM, INPP1, ICOSLG, LRP1, MMP12, GBP2, GZMB, EPO, CXCL9, LGALS4, VIM, GZMH, MFAP5, CD46, SSB, CTSS, JAM2, KIR2DL3, BGN, PDGFC, RAD23B, FAM3B, GALNT7, VAT1, HBEGF, MIA, TPT1, ILIR1, CD83, MLN, CD200, CLEC4D, CLEC4C, CXLC10, BTN2A1, TFF2, CTRC, EPHX2, CHEK2, MFAP3, DCN, LGALS1, THBD, CDH1, FCN2, IL6R, ILKAP, FOSB, MASP1, DRAXIN, ABHD14B, CD274, ADAM8, SCARF 2, RGMA, DSC2, AKT3, NTF4, TBLX1, LYPD8, LYAR, ITGB1BP1, GH2, EPHA2, LRRC25, ALPP, LAG3, KLK4, CD300LF, HBQ1, FURIN, FLT4, FGFR2, NECTIN4, P4HB, ACTN4, WAS, HLA-E, PARP1, NT5C3A, CASP2, OSM, HSD11B1, SLAMF7, IL32, CCL3, TRIM21, TRAF2, ALDH3A1, EDAR, KLRB1, DFFA, TGFB1, REG4, CXCL1, CEP43, IRAG2, TP53INP1, GLO1, GRK5, PDGFRA, SDC4, PRKAR1A, FADD, GDF2, FAM3C, CASP3, MB, PAM, SERPINE1, TGFB1, ITGB1, CD93, ATP6V1F, BAX, NDRG1, SIRT5, MDGA1, STAMBP, EREG, IMPA1, CRADD, TNR, NPM1, PRDX1, PSME1, LAYN, CDH15, VTA1, NSFL1C, MSR1, TFF1, CLEC14A, bin2, PARK7, CCT5, SFTPA2, CRACR2A, SUGT1, CHAC2, GNE, FMR1, CDC27, CEP20, TBC1D23, UBAC1, OMG, VPS37A, TMPRSS15, KIFBP, CD207, CNPY4, CALCOCO1, CPE, METAP2, PPY, CDC37, FGFBP1, FGF5, SMPDL3A, NPPB, AMY2B, GUSB, ICAM2, CELA3A, PROC, PAEP, and ASAH2.
A method for detecting one or more biomarkers, comprising:
- contacting a sample with at least one molecule having affinity for the the biomarker, the biomarker selected from one or more of LRRN1, VASH, NELL2, DNAJB8, IGFBP1, PTPRN2, AFP, CD74, BST2, CD99, KIR3DL1, RBP2, CES2, NCS1, C4BPB, RAB6A, CCL4, FABP2, FUCA1, REG3A, GGA1, ATXN10, MUC13, ODAM, ARID4B, CCL2, CLEC11A, ITGAM, INPP1, ICOSLG, LRP1, MMP12, GBP2, GZMB, EPO, CXCL9, LGALS4, VIM, GZMH, MFAP5, CD46, SSB, CTSS, JAM2, KIR2DL3, BGN, PDGFC, RAD23B, FAM3B, GALNT7, VATI, HBEGF, MIA, TPT1, ILIR1, CD83, MLN, CD200, CLEC4D, CLEC4C, CXLC10, BTN2A1, TFF2, CTRC, EPHX2, CHEK2, MFAP3, DCN, LGALS1, THBD, CDH1, FCN2, IL6R, ILKAP, FOSB, MASP1, DRAXIN, ABHD14B, CD274, ADAM8, SCARF 2, RGMA, DSC2, AKT3, NTF4, TBLX1, LYPD8, LYAR, ITGB1BP1, GH2, EPHA2, LRRC25, ALPP, LAG3, KLK4, CD300LF, HBQ1, FURIN, FLT4, FGFR2, NECTIN4, P4HB, ACTN4, WAS, HLA-E, PARP1, NT5C3A, CASP2, OSM, HSD11B1, SLAMF7, IL32, CCL3, TRIM21, TRAF2, ALDH3A1, EDAR, KLRB1, DFFA, TGFB1, REG4, CXCL1, CEP43, IRAG2, TP53INP1, GLO1, GRK5, PDGFRA, SDC4, PRKAR1A, FADD, GDF2, FAM3C, CASP3, MB, PAM, SERPINE1, TGFB1, ITGB1, CD93, ATP6V1F, BAX, NDRG1, SIRT5, MDGA1, STAMBP, EREG, IMPA1, CRADD, TNR, NPM1, PRDX1, PSME1, LAYN, CDH15, VTA1, NSFL1C, MSR1, TFF1, CLEC14A, bin2, PARK7, CCT5, SFTPA2, CRACR2A, SUGT1, CHAC2, GNE, FMR1, CDC27, CEP20, TBC1D23, UBAC1, OMG, VPS37A, TMPRSS15, KIFBP, CD207, CNPY4, CALCOCO1, CPE, METAP2, PPY, CDC37, FGFBP1, FGF5, SMPDL3A, NPPB, AMY2B, GUSB, ICAM2, CELA3A, PROC, PAEP, and ASAH2.
A method of for diagnosing or predicting NEC in a patient at risk thereof, comprising:
- obtaining a sample of circulating proteins from the patient;
- identifying the presence of one or more biomarkers in the sample to determine a biomarker signature;
- and
- comparing the patient biomarker signature to a diagnostic and/or predictive signature to determine the presence of NEC and/or risk of developing NEC.
The method of claim 15, where in the signal demonstrates that at least one biomarker's expression is downregulated.
Dependencies are inferred from the claim text.